NICE QIPP about Lipitor. Robert Trotter. Clinical Effectiveness Consultant

Size: px
Start display at page:

Download "NICE QIPP about Lipitor. Robert Trotter. Clinical Effectiveness Consultant"

Transcription

1 NICE QIPP about Lipitor Robert Trotter Clinical Effectiveness Consultant LIP2894c Date of preparation: April 2009 Prescribing information for atorvastatin is available on the last slide

2 Roadmap Background Financial Clinical NICE Lipitor in ACS and stable CVD Clinical data Health economics

3 Opportunity Reference -3-

4 Pressures -4-

5 Standardised Mortality Rates for CHD Blackpool 139 Central Lancashire 100 North Lancashire 105 Reference -5-

6 A 0.5mmol/L difference in LDL-C could lead to an 11% difference in major vascular events and a 6% difference in all cause mortality 50% Major vascular events are MI, stroke and revascularisation Proportional Change in Event Rate (SE) 40% 30% 20% 10% 0% ,056 patients from 14 trials over 5 years -10% Change in LDL Cholesterol (mmol/l) CTT Collaborators (2005) Lancet; 366: Adapted from CTT Collaborators. Lancet. 2005; 366:

7 Cholesterol Treatment Trialists (CTT) meta analysis 90,056 patients, 14 trials, 5 years For every 1mmol/L reduction in LDL-C 12% reduction in all cause mortality 19% reduction in coronary mortality 21% reduction in major vascular events 23% reduction in major coronary events 17% reduction in stroke 24% reduction in revascularisation while lowering LDL-C from 4mmol/L to 3mmol/L reduces the risk of vascular events by about 23%, lowering LDL-C from 3mmol/L to 2mmol/L also reduces (residual) risk by about 23% Cholesterol Treatment Trialists Collaborators, Lancet 2005

8 NICE Lipid Modification Clinical Guidelines (May 2008) Primary Prevention Secondary Prevention ACS Start S40* or a drug of similar efficacy and cost for adults >40 yrs with >20% 10 year CVD risk (Framingham) -No target level for TC or LDL-C -No repeat lipid profile but review management according to clinical judgement and patient preference If statins not tolerated for primary prevention, consider: fibrates, anion exchange resins, ezetimibe Start S40* or a drug of similar efficacy and cost If TC not <4mmol/L or LDL-C not <2mmol/L consider up-titrating to S80 or a drug of similar efficacy and cost Patients with clinical evidence of: -CHD -Stroke or transient ischaemic episode -Peripheral artery disease Use an audit level of TC = 5mmol/L to assess progress in groups with CVD. Recognise that less than half will achieve TC < 4mmo/L or LDL-C < 2mmol/L Identified by NICE as: -New-onset angina -Unstable angina -Myocardial Infarction Offer higher intensity statin** without delay irrespective of baseline cholesterol Measure lipid levels at 3 months If statins are not tolerated for secondary prevention, consider: fibrates, anion exchange resins, nicotinic acid, ezetimibe Be mindful of: 1) Patient preference 2) Co-morbidities 3) Other therapies 4) Benefit and risks NICE recommend lipid lowering drugs for which there is evidence in clinical trials of a beneficial effect on CVD morbidity and mortality. * If there are potential drug interactions or 40mg simvastatin is contraindicated, offer a lower dose of simvastatin or pravastatin ** Higher intensity statins are statins used in doses that produce greater cholesterol lowering than simvastatin 40mg, for example simvastatin 80mg S40 = simvastatin 40; S80 = simvastatin 80mg; ACS = Acute Coronary Syndrome Flow chart adapted from NICE CG67 Quick Reference Guide Accessed September 2008 NICE CG67 Lipid Modification Clinical Guidelines Accessed September 2008

9 Most patients will not achieve NICE recommendations of lowering TC to <4mmol/L for secondary prevention with generic statins alone NICE analysis suggests that in patients with established CVD: 31% will attain TC<4mmol/L on simvastatin 40mg 1 37% will reach TC<4mmol/L on simvastatin 80mg 1 1 NICE CG67 Costing Report section Accessed September 2008

10 The Law meta-analysis of 164 randomised statin trials Law et al (2003) BMJ 326: Jones et al (1998) Am J Cardiol 81:

11 NICE Type II Diabetes Clinical Guidelines (May 2008) Age >40 diabetic and low CV risk (consider low CV risk if none of the risk factors listed below apply) Age >40 diabetic and high CV risk (consider high CV risk if one of the risk factors listed below apply) List of risk factors overweight hypertensive (>140/80mmHg despite anti-hypertensive therapy) microalbuminuria smoker high-risk lipid profile history of CV disease family history of CV disease Assess CV risk with UKPDS. If CV risk >20% over 10 yrs No CV risk assessment required Offer S40 or a statin of similar efficacy and cost If not at target uptitrate to S80 If there is CVD or albuminuria, intensify therapy with a more effective statin or ezetimibe to achieve cholesterol targets Assess lipid profile at 1-3 months after starting treatment Treat to achieve target TC< 4mmol/L or LDL-C<2mmol/L S40 = simvastatin 40; S80 = simvastatin 80mg Flow diagram adapted from NICE CG66 Quick Reference Guide Accessed September, 2008 NICE CG66 Accessed September, 2008

12 PROVE IT: Death, MI or ACS rehospitalisation % of patients with death, MI or rehospitalisation for ACS Early Benefit Acute Phase Late Benefit Chronic Phase ARR 4.3% NNT =24 over 2 years Pravastatin 40 mg (LDL-C 2.5mmol/L) Atorvastatin 80 mg (LDL-C 1.6mmol/L) 20.0% 15.7% 24% RRR HR 0.76 ( ) P= Ray et al (2005) JACC 46: Months following randomisation

13 An early benefit becomes apparent at day 15 and significant at day 30 % of patients with death, MI or rehospitalisation for ACS Pravastatin 40 mg 4.2 % Atorvastatin 80 mg 3.0 % 28% RRR HR 0.72 ( ) P = Days following randomisation Ray et al (2005) JACC 46:

14 A second late benefit was also demonstrated for patients remaining on atorvastatin % of patients with death, MI or rehospitalisation for ACS Months following randomisation Pravastatin 40 mg 13.1% Atorvastatin 80 mg 9.6% 28% RRR HR 0.72 ( ) P= Ray et al (2005) JACC 46: *Analysis excluding patients with events in the first 6 months

15 Post MI patients had significantly fewer events on high dose atorvastatin vs moderate dose simvastatin over 5 yrs Post hoc analysis of 999 post MI patients in the IDEAL trial (within 2 months of MI) Cumulative Hazard of MI (%) 20 Simvastatin 20-40mg Atorvastatin 80mg NNT 18 over 5 years 46% relative risk reduction 0 HR = 0.54 (95% CI = 0.35, 0.82), P= Years Since Randomisation Pedersen et al. Presented at World Congress of Cardiology 2006

16 PROVE IT- total costs (drug + hospitalisation) per patient ,500 3,184 3,236 3,000 Mean cost ( ) 2,500 2,000 1,500 1,000 = hospitalisation costs = drug costs Atorvastatin n=2,099 Pravastatin n=2,063 Presented at ISPOR 2006, Abstract A193, Value in Health, 9(6)

17 Conclusions from ACS studies The evidence for intensive lipid lowering with atorvastatin in patients with acute coronary syndrome is significant and clinically compelling 1,2 The benefit appears rapidly and is maintained long term 1,2 Less intensive lipid lowering appears to increase risk in this patient group in comparison to intensive therapy 1-2 NICE recommend that patients with ACS should be treated with a higher intensity statin* without delaying until lipid levels are available 3 1 Ray et al (2005) JACC 46: Pedersen et al. Presented at World Congress of Cardiology NICE CG67 Lipid Modification Clinical Guidelines Accessed March 2009

18 Abbreviated prescribing information for atorvastatin Abbreviated prescribing information: Lipitor Presentation: Lipitor is supplied as film coated tablets containing 10mg, 20mg, 40mg or 80mg of atorvastatin. Indications: In patients unresponsive to diet and other non-pharmacological measures, Lipitor is indicated for the reduction of elevated total cholesterol, LDL-cholesterol, apolipoprotein B, and triglycerides in adults and children aged 10 years and older with primary hypercholesterolaemia, heterozygous familial hypercholesterolaemia or combined (mixed) hyperlipidaemia. Lipitor also raises HDL-cholesterol and lowers the LDL/HDL and total cholesterol/hdl ratios. Lipitor is also indicated for the reduction of elevated total cholesterol, LDL-cholesterol, and apolipoprotein B in patients with homozygous familial hypercholesterolaemia. Lipitor is indicated for reducing the risk of cardiovascular events in patients with Type II diabetes and one additional risk factor, without clinically evident coronary heart disease, irrespective of whether cholesterol is raised. Dosage: The usual starting dose is one Lipitor 10mg tablet daily. Doses should be individualised according to baseline LDL-C levels, the goal of therapy, and patient response. Doses may be given at any time of the day with or without food. The maximum daily dose is 80mg. For patients taking drugs that increase plasma exposure to atorvastatin the starting dose should not exceed 10mg and maximum dose of less than 80mg may have to be considered. Doses above 20mg/day have not been investigated in patients aged <18 years. In primary prevention trials, the dose was 10mg/day. Contraindications: Hypersensitivity to any of the ingredients, active liver disease, unexplained elevations in serum transaminases, pregnancy and breast-feeding and in women of child-bearing potential not using contraception. Warning and precautions: Liver function tests should be performed before initiation and periodically thereafter and in patients who show signs and symptoms of liver injury (monitor raised transaminases until they return to normal). Drug dosage should be reduced or therapy discontinued if persistent elevations occur above 3-times the upper limit of normal. Lipitor should be used with caution in patients with a history of liver disease and/or alcoholism. For patients with prior haemorrhagic stroke or lacunar infarct, the balance of risks and benefits of atorvastatin 80 mg is uncertain and the potential risk of haemorrhagic stroke should be carefully considered before initiating treatment. Patients with signs and symptoms of myopathy should have their creatine phosphokinase (CPK) levels monitored. Lipitor should be discontinued if CPK levels are markedly or persistently raised or myopathy is diagnosed or suspected. Lipitor should be prescribed with caution in patients with pre-disposing factors for rhabdomyolysis. Risk of myopathy may increase when administered with certain medications that increase the plasma concentration of atorvastatin. If co-administration is required a dose reduction or if not practical a temporary suspension should be considered; the starting dose of atorvastatin should be 10 mg. In the case of ciclosporin, clarithromycin and itraconazole a lower maximum dose should be used. Although interaction studies with atorvastatin and fusidic acid have not been conducted, severe muscle problems such as rhabdomyolysis have been reported in post-marketing experience with this combination - therefore patients should be closely monitored and temporary suspension of atorvastatin treatment may be appropriate. As with other statins, rhabdomyolysis with acute renal failure has been reported. Patients with galactose intolerance, Lapp lactose deficiency or glucose-galactose malabsorption should not take this product. Pregnancy and lactation: Lipitor is contraindicated in pregnancy and lactation. Side effects: Side effects most frequently reported in controlled clinical studies: constipation, flatulence, dyspepsia, abdominal pain, headache, nausea, myalgia, asthenia, diarrhoea, insomnia, elevations in ALT and CPK levels. Other side effects have been reported in clinical trials and post-marketing (See Summary of Product Characteristics). Legal category: POM. Date of Revision: February 2009 Package quantities, marketing authorisation numbers and basic NHS price: Lipitor 10mg (28 tablets), PL16051/ , Lipitor 20mg (28 tablets), PL16051/ , Lipitor 40mg (28 tablets) PL16051/ , Lipitor 80mg (28 tablets) PL 16051/ Marketing Authorisation Holder: Pfizer Ireland Pharmaceuticals, Pottery Road, Dun Laoghaire, Co. Dublin, Ireland. Lipitor is a registered trade mark. Further information is available on request from: Medical Information, Pfizer Limited, Walton Oaks, Dorking Road, Tadworth, Surrey KT20 7NS. Ref: LR 10_0. Adverse events should be reported. Reporting forms and information can be found at Adverse events should also be reported to Pfizer Medical Information on Date of preparation: April 2009 LIP2894c

Scientific conclusions

Scientific conclusions Annex II Scientific conclusions and grounds for amendment of the summary of product characteristics, labelling and package leaflet presented by the European Medicines Agency 24 Scientific conclusions Overall

More information

Royal Wolverhampton Hospital Adult Lipid Lowering Therapy Guidelines Lipid Lowering Therapy for the Prevention of Cardiovascular Disease

Royal Wolverhampton Hospital Adult Lipid Lowering Therapy Guidelines Lipid Lowering Therapy for the Prevention of Cardiovascular Disease Royal Wolverhampton Hospital Adult Lipid Lowering Therapy Guidelines 1 This guideline is intended to assist rational and cost-effective prescribing of lipid regulating medications across both primary and

More information

Volume 2; Number 11 July 2008

Volume 2; Number 11 July 2008 Volume 2; Number 11 July 2008 CONTENTS Page 1 NICE Clinical Guideline 67: Lipid Modification (May 2008) Page 7 NICE Technology Appraisal 132: Ezetimibe for the treatment of primary (heterozygous familial

More information

The legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION. 6 October 2010

The legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION. 6 October 2010 The legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION 6 October 2010 CRESTOR 5 mg, film-coated tablet B/30 (CIP code: 369 853-8) B/90 (CIP code: 391 690-0) CRESTOR 10 mg,

More information

ESC Geoffrey Rose Lecture on Population Sciences Cholesterol and risk: past, present and future

ESC Geoffrey Rose Lecture on Population Sciences Cholesterol and risk: past, present and future ESC Geoffrey Rose Lecture on Population Sciences Cholesterol and risk: past, present and future Rory Collins BHF Professor of Medicine & Epidemiology Clinical Trial Service Unit & Epidemiological Studies

More information

FORTH VALLEY. LIPID LOWERING GUIDELINE v5 2016

FORTH VALLEY. LIPID LOWERING GUIDELINE v5 2016 FORTH VALLEY LIPID LOWERING GUIDELINE v5 2016 This guideline applies to people over 16 years of age. This guideline is not intended to serve as a standard of medical care or be applicable in every situation.

More information

This is a lipid lowering drug strategy which should only be used within an overall lifestyle and clinical management strategy.

This is a lipid lowering drug strategy which should only be used within an overall lifestyle and clinical management strategy. Treatment Guideline Statin Prescribing Objective These guidelines represent the views of the Gloucestershire Hospitals NHS Foundation Trust, which were arrived at after consideration of the available evidence

More information

Issue date: January Review date: November Statins for the prevention of cardiovascular events. Technology Appraisal 94

Issue date: January Review date: November Statins for the prevention of cardiovascular events. Technology Appraisal 94 Issue date: January 2006 Review date: November 2008 Statins for the prevention of cardiovascular events Technology Appraisal 94 Technology Appraisal 94 Statins for the prevention of cardiovascular events

More information

rosuvastatin, 5mg, 10mg, 20mg, film-coated tablets (Crestor ) SMC No. (725/11) AstraZeneca UK Ltd.

rosuvastatin, 5mg, 10mg, 20mg, film-coated tablets (Crestor ) SMC No. (725/11) AstraZeneca UK Ltd. rosuvastatin, 5mg, 10mg, 20mg, film-coated tablets (Crestor ) SMC No. (725/11) AstraZeneca UK Ltd. 09 September 2011 The Scottish Medicines Consortium (SMC) has completed its assessment of the above product

More information

The JUPITER trial: What does it tell us? Alice Y.Y. Cheng, MD, FRCPC January 24, 2009

The JUPITER trial: What does it tell us? Alice Y.Y. Cheng, MD, FRCPC January 24, 2009 The JUPITER trial: What does it tell us? Alice Y.Y. Cheng, MD, FRCPC January 24, 2009 Learning Objectives 1. Understand the role of statin therapy in the primary and secondary prevention of stroke 2. Explain

More information

Primary Prevention Patients aged 85yrs and over

Primary Prevention Patients aged 85yrs and over Rotherham Guideline for the management of Non-Familial Hypercholesterolaemia Type 1 Diabetes Offer lifestyle advice Over 40yrs of age? Diabetic for more than 10 years? Established nephropathy? Other CVD

More information

LDL cholesterol and cardiovascular outcomes?

LDL cholesterol and cardiovascular outcomes? LDL cholesterol and cardiovascular outcomes? Prof Kausik Ray, BSc (hons), MBChB, FRCP, MD, MPhil (Cantab), FACC, FESC Professor of Cardiovascular Disease Prevention St Georges University of London Honorary

More information

Coronary Heart Disease and Stroke, Primary and Secondary Prevention Guidelines (Cholesterol)

Coronary Heart Disease and Stroke, Primary and Secondary Prevention Guidelines (Cholesterol) CLINICAL GUIDELINE Coronary Heart Disease and Stroke, Primary and Secondary Prevention Guidelines (Cholesterol) A guideline is intended to assist healthcare professionals in the choice of disease-specific

More information

Elements for a public summary

Elements for a public summary VI.2 Elements for a public summary VI.2.1 Overview of disease epidemiology Cardiovascular disease (CVD) is responsible for one-third of global deaths and is a leading and increasing contributor to the

More information

Rosuvastatin 5 mg, 10 mg and 20 mg Tablet

Rosuvastatin 5 mg, 10 mg and 20 mg Tablet Rosuvastatin 5 mg, 10 mg and 20 mg Tablet Description is a preparation of Rosuvastatin. Rosuvastatin is a member of the drug class of statins, used in combination with exercise, diet, and weight-loss to

More information

Cardiovascular risk reduction in diabetes Lipids (NICE CG181)

Cardiovascular risk reduction in diabetes Lipids (NICE CG181) Cardiovascular risk reduction in diabetes Lipids (NICE CG181) Primary Prevention T1DM Offer Atorvastatin 20mg if >40 years old Diabetes duration >10 years Established nephropathy Other CVS risk factors

More information

NATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE. Overview

NATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE. Overview NATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE Overview Ezetimibe for the treatment of primary (heterozygous familial and non-familial) hypercholesterolaemia The overview is written by members of

More information

NATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE

NATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE NATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE QUALITY AND OUTCOMES FRAMEWORK (QOF) INDICATOR DEVELOPMENT PROGRAMME Briefing paper QOF indicator area: Primary prevention of CVD Potential output:

More information

2013 ACC AHA LIPID GUIDELINE JAY S. FONTE, MD

2013 ACC AHA LIPID GUIDELINE JAY S. FONTE, MD 2013 ACC AHA LIPID GUIDELINE JAY S. FONTE, MD How do you interpret my blood test results? What are our targets for these tests? Before the ACC/AHA Lipid Guidelines A1c:

More information

CHOLESTAGEL 625 mg Genzyme

CHOLESTAGEL 625 mg Genzyme CHOLESTAGEL 625 mg Genzyme 1. NAME OF THE MEDICINAL PRODUCT Cholestagel 625 mg film-coated tablets 2. QUALITATIVE AND QUANTITATIVE COMPOSITION Each tablet contains 625 mg colesevelam hydrochloride (hereafter

More information

Package leaflet: Information for the user. Pravastatin Actavis 20 mg and 40 mg tablets (pravastatin sodium)

Package leaflet: Information for the user. Pravastatin Actavis 20 mg and 40 mg tablets (pravastatin sodium) PACKAGE LEAFLET Package leaflet: Information for the user Pravastatin Actavis 20 mg and 40 mg tablets (pravastatin sodium) Read all of this leaflet carefully before you start taking this medicine because

More information

CLINICAL OUTCOME Vs SURROGATE MARKER

CLINICAL OUTCOME Vs SURROGATE MARKER CLINICAL OUTCOME Vs SURROGATE MARKER Statin Real Experience Dr. Mostafa Sherif Senior Medical Manager Pfizer Egypt & Sudan Objective Difference between Clinical outcome and surrogate marker Proper Clinical

More information

CVD risk assessment using risk scores in primary and secondary prevention

CVD risk assessment using risk scores in primary and secondary prevention CVD risk assessment using risk scores in primary and secondary prevention Raul D. Santos MD, PhD Heart Institute-InCor University of Sao Paulo Brazil Disclosure Honoraria for consulting and speaker activities

More information

SECONDARY PREVENTION OF CORONARY HEART DISEASE AND ISCHAEMIC STROKE/TIA

SECONDARY PREVENTION OF CORONARY HEART DISEASE AND ISCHAEMIC STROKE/TIA PRIMARY PREVENTION OF CHD AND STROKE IN HIGH RISK PATIENTS Random non fasting test for total cholesterol, HDL cholesterol (TC:HDL ratio) and LFTs If cholesterol > 7.5 mmol/l or LDL C 5mmol/l exclude secondary

More information

Update on Dyslipidemia and Recent Data on Treating the Statin Intolerant Patient

Update on Dyslipidemia and Recent Data on Treating the Statin Intolerant Patient Update on Dyslipidemia and Recent Data on Treating the Statin Intolerant Patient Steven E. Nissen MD Chairman, Department of Cardiovascular Medicine Cleveland Clinic Disclosure Consulting: Many pharmaceutical

More information

CONTRAINDICATIONS: Hypersensitivity to the active substance or to any of the excipients

CONTRAINDICATIONS: Hypersensitivity to the active substance or to any of the excipients Galvus PRESENTATION: Each tablet contains 50 mg of Vildagliptin INDICATIONS: For the treatment of type 2 diabetes mellitus in adults: i) As monotherapy in patients inadequately controlled by diet and exercise

More information

Approach to Dyslipidemia among diabetic patients

Approach to Dyslipidemia among diabetic patients Approach to Dyslipidemia among diabetic patients Farzad Hadaegh, MD, Professor of Internal Medicine & Endocrinology Prevention of Metabolic Disorders Research Center, Research Institute for Endocrine Sciences

More information

Is Lower Better for LDL or is there a Sweet Spot

Is Lower Better for LDL or is there a Sweet Spot Is Lower Better for LDL or is there a Sweet Spot ALAN S BROWN MD, FACC FNLA FAHA FASPC DIRECTOR, DIVISION OF CARDIOLOGY ADVOCATE LUTHERAN GENERAL HOSPITAL, PARK RIDGE, ILLINOIS DIRECTOR OF CARDIOLOGY,

More information

SIGN 149 Risk estimation and the prevention of cardiovascular disease. Quick Reference Guide July Evidence

SIGN 149 Risk estimation and the prevention of cardiovascular disease. Quick Reference Guide July Evidence SIGN 149 Risk estimation and the prevention of cardiovascular disease Quick Reference Guide July 2017 Evidence ESTIMATING CARDIOVASCULAR RISK R Individuals with the following risk factors should be considered

More information

PIEDMONT ACCESS TO HEALTH SERVICES, INC. Guidelines for Screening and Management of Dyslipidemia

PIEDMONT ACCESS TO HEALTH SERVICES, INC. Guidelines for Screening and Management of Dyslipidemia PIEDMONT ACCESS TO HEALTH SERVICES, INC. Policy Number: 01-09-021 SUBJECT: Guidelines for Screening and Management of Dyslipidemia EFFECTIVE DATE: 04/2008 REVIEWED/REVISED: 04/12/10, 03/17/2011, 4/10/2012,

More information

How would you manage Ms. Gold

How would you manage Ms. Gold How would you manage Ms. Gold 32 yo Asian woman with dyslipidemia Current medications: Simvastatin 20mg QD Most recent lipid profile: TC = 246, TG = 100, LDL = 176, HDL = 50 What about Mr. Williams? 56

More information

See Important Reminder at the end of this policy for important regulatory and legal information.

See Important Reminder at the end of this policy for important regulatory and legal information. Clinical Policy: Reference Number: CP.HNMC.05 Effective Date: 11.16.16 Last Review Date: 11.17 Line of Business: Medicaid Medi-Cal Revision Log See Important Reminder at the end of this policy for important

More information

nicotinic acid 375mg, 500mg, 750mg, 1000mg modified release tablet (Niaspan ) No. (93/04) Merck

nicotinic acid 375mg, 500mg, 750mg, 1000mg modified release tablet (Niaspan ) No. (93/04) Merck Scottish Medicines Consortium Resubmission nicotinic acid 375mg, 500mg, 750mg, 1000mg modified release tablet (Niaspan ) No. (93/04) Merck New formulation 6 January 2006 The Scottish Medicines Consortium

More information

Dyslipidemia in the light of Current Guidelines - Do we change our Practice?

Dyslipidemia in the light of Current Guidelines - Do we change our Practice? Dyslipidemia in the light of Current Guidelines - Do we change our Practice? Dato Dr. David Chew Soon Ping Senior Consultant Cardiologist Institut Jantung Negara Atherosclerotic Cardiovascular Disease

More information

Should we prescribe aspirin and statins to all subjects over 65? (Or even all over 55?) Terje R.Pedersen Oslo University Hospital Oslo, Norway

Should we prescribe aspirin and statins to all subjects over 65? (Or even all over 55?) Terje R.Pedersen Oslo University Hospital Oslo, Norway Should we prescribe aspirin and statins to all subjects over 65? (Or even all over 55?) Terje R.Pedersen Oslo University Hospital Oslo, Norway The Polypill A strategy to reduce cardiovascular disease by

More information

Andrew Cohen, MD and Neil S. Skolnik, MD INTRODUCTION

Andrew Cohen, MD and Neil S. Skolnik, MD INTRODUCTION 2 Hyperlipidemia Andrew Cohen, MD and Neil S. Skolnik, MD CONTENTS INTRODUCTION RISK CATEGORIES AND TARGET LDL-CHOLESTEROL TREATMENT OF LDL-CHOLESTEROL SPECIAL CONSIDERATIONS OLDER AND YOUNGER ADULTS ADDITIONAL

More information

Introduction. Objective. Critical Questions Addressed

Introduction. Objective. Critical Questions Addressed Introduction Objective To provide a strong evidence-based foundation for the treatment of cholesterol for the primary and secondary prevention of ASCVD in women and men Critical Questions Addressed CQ1:

More information

Review of guidelines for management of dyslipidemia in diabetic patients

Review of guidelines for management of dyslipidemia in diabetic patients 2012 international Conference on Diabetes and metabolism (ICDM) Review of guidelines for management of dyslipidemia in diabetic patients Nan Hee Kim, MD, PhD Department of Internal Medicine, Korea University

More information

An update on lipidology and cardiovascular risk management. Lipids, Metabolism & Vascular Risk Section - Royal Society of Medicine

An update on lipidology and cardiovascular risk management. Lipids, Metabolism & Vascular Risk Section - Royal Society of Medicine An update on lipidology and cardiovascular risk management Lipids, Metabolism & Vascular Risk Section - Royal Society of Medicine National and international lipid modification guidelines: A critical appraisal

More information

BEST PRACTICE MANAGEMENT: CARDIOVASCULAR RISKS

BEST PRACTICE MANAGEMENT: CARDIOVASCULAR RISKS BEST PRACTICE MANAGEMENT: CARDIOVASCULAR RISKS Neil R Poulter ICCH, Imperial College London BHIVA: October 10th, 2008 Background CVD is the biggest single killer in the world CVD rates are increasing High

More information

Cardiovascular risk assessment and the modification of blood lipids for the primary and secondary prevention of cardiovascular disease

Cardiovascular risk assessment and the modification of blood lipids for the primary and secondary prevention of cardiovascular disease Issue date: May 2008 Lipid modification Cardiovascular risk assessment and the modification of blood lipids for the primary and secondary prevention of cardiovascular disease NICE clinical guideline 67

More information

Young high risk patients the role of statins Dr. Mohamed Jeilan

Young high risk patients the role of statins Dr. Mohamed Jeilan Young high risk patients the role of statins Dr. Mohamed Jeilan KCS Congress: Impact through collaboration CONTACT: Tel. +254 735 833 803 Email: kcardiacs@gmail.com Web: www.kenyacardiacs.org Disclosures

More information

Death is inevitable but premature death is not. Sir Richard Doll

Death is inevitable but premature death is not. Sir Richard Doll Welcome to the Diabetes Care for You webinar Please log onto the conference call so you can hear our presenter From any SCFT Cisco phone dial 800800 From a mobile phone or any other phone dial 01273 242

More information

Lipids & Hypertension Update

Lipids & Hypertension Update Lipids & Hypertension Update No financial disclosures Michael W. Cullen, MD, FACC Senior Associate Consultant, Assistant Professor of Medicine Mayo Clinic Department of Cardiovascular Diseases 34 th Annual

More information

Technology appraisal guidance Published: 22 June 2016 nice.org.uk/guidance/ta394

Technology appraisal guidance Published: 22 June 2016 nice.org.uk/guidance/ta394 Evolocumab for treating primary hypercholesterolaemia and mixed dyslipidaemia Technology appraisal guidance Published: 22 June 2016 nice.org.uk/guidance/ta394 NICE 2017. All rights reserved. Subject to

More information

Valdoxan (agomelatine) in the treatment of Major Depressive Episodes in Adults. Prescriber Guide Information for Healthcare Professionals

Valdoxan (agomelatine) in the treatment of Major Depressive Episodes in Adults. Prescriber Guide Information for Healthcare Professionals Important information Do not discard! Valdoxan (agomelatine) in the treatment of Major Depressive Episodes in Adults Prescriber Guide Information for Healthcare Professionals Recommendations regarding:

More information

Lipid Studies That Rocked My World Gabor Gyenes Medicine Grand Rounds May 27, 2011

Lipid Studies That Rocked My World Gabor Gyenes Medicine Grand Rounds May 27, 2011 Lipid Studies That Rocked My World Gabor Gyenes Medicine Grand Rounds May 27, 2011 Disclosure of Conflicts of Interest I have received travel grants and honoraria from sanofi-aventis, Pfizer, Servier,

More information

HYPERLIPIDEMIA IN THE OLDER POPULATION NICOLE SLATER, PHARMD, BCACP AUBURN UNIVERSITY, HARRISON SCHOOL OF PHARMACY JULY 16, 2016

HYPERLIPIDEMIA IN THE OLDER POPULATION NICOLE SLATER, PHARMD, BCACP AUBURN UNIVERSITY, HARRISON SCHOOL OF PHARMACY JULY 16, 2016 HYPERLIPIDEMIA IN THE OLDER POPULATION NICOLE SLATER, PHARMD, BCACP AUBURN UNIVERSITY, HARRISON SCHOOL OF PHARMACY JULY 16, 2016 NOTHING TO DISCLOSE I, Nicole Slater, have no actual or potential conflict

More information

2013 Cholesterol Guidelines. Anna Broz MSN, RN, CNP, AACC Adult Certified Nurse Practitioner North Ohio Heart, Inc.

2013 Cholesterol Guidelines. Anna Broz MSN, RN, CNP, AACC Adult Certified Nurse Practitioner North Ohio Heart, Inc. 2013 Cholesterol Guidelines Anna Broz MSN, RN, CNP, AACC Adult Certified Nurse Practitioner North Ohio Heart, Inc. Disclosures Speaker Gilead Sciences NHLBI Charge to the Expert Panel Evaluate higher quality

More information

Statins ARE Enough For The Prevention of CVD! Professor Kausik Ray Imperial College London, UK

Statins ARE Enough For The Prevention of CVD! Professor Kausik Ray Imperial College London, UK 1 Disclosures Advisory boards PCSK9- Sanofi/ Regeneron, Amgen, Pfizer, Roche, MSD NLI/ SC member for Odyssey- (Sanofi/ Regeneron), Roche Investigator initiated research grant support (Sanofi/Regeneron/

More information

Pravastatin Sodium 10 mg Tablets Version 7 SUMMARY OF PRODUCT CHARACTERISTICS

Pravastatin Sodium 10 mg Tablets Version 7 SUMMARY OF PRODUCT CHARACTERISTICS SUMMARY OF PRODUCT CHARACTERISTICS Product Summary 1. NAME OF THE MEDICINAL PRODUCT Pravastatin Sodium 10 mg Tablets 2. QUALITATIVE AND QUANTITATIVE COMPOSITION Each tablet contains pravastatin sodium

More information

STATIN UTILIZATION MANAGEMENT CRITERIA

STATIN UTILIZATION MANAGEMENT CRITERIA STATIN UTILIZATION MANAGEMENT CRITERIA DRUG CLASS: HMG Co-A Reductase Inhibitors & Combinations Agents which require prior review: Advicor (niacin extended-release/lovastatin) Crestor (rosuvastatin)(5mg,10mg,

More information

Case Presentation. Rafael Bitzur The Bert W Strassburger Lipid Center Sheba Medical Center Tel Hashomer

Case Presentation. Rafael Bitzur The Bert W Strassburger Lipid Center Sheba Medical Center Tel Hashomer Case Presentation Rafael Bitzur The Bert W Strassburger Lipid Center Sheba Medical Center Tel Hashomer Case Presentation 50 YO man NSTEMI treated with PCI 1 month ago Medical History: Obesity: BMI 32,

More information

Lipid Panel Management Refresher Course for the Family Physician

Lipid Panel Management Refresher Course for the Family Physician Lipid Panel Management Refresher Course for the Family Physician Objectives Understand the evidence that was evaluated to develop the 2013 ACC/AHA guidelines Discuss the utility and accuracy of the new

More information

Sponsor Novartis. Generic Drug Name Fluvastatin. Therapeutic Area of Trial Dyslipidemia

Sponsor Novartis. Generic Drug Name Fluvastatin. Therapeutic Area of Trial Dyslipidemia Page 1 Sponsor Novartis Generic Drug Name Fluvastatin Therapeutic Area of Trial Dyslipidemia Approved Indication Therapeutic area and approved indications in Germany: Hypercholesterolemia (HC), combined

More information

P A C K A G E L E A F L E T INFORMATION FOR THE USER. Simvastatin Genericon 20 mg - film-coated tablets

P A C K A G E L E A F L E T INFORMATION FOR THE USER. Simvastatin Genericon 20 mg - film-coated tablets P A C K A G E L E A F L E T INFORMATION FOR THE USER Simvastatin Genericon 20 mg - film-coated tablets Read all of this leaflet carefully before you start taking this medicine. Keep this leaflet. You may

More information

Weigh the benefit of statin treatment: LDL & Beyond

Weigh the benefit of statin treatment: LDL & Beyond Weigh the benefit of statin treatment: LDL & Beyond Duk-Woo Park, MD, PhD Heart Institute, University of Ulsan College of Medicine, Asan Medical, Seoul, Korea FOURIER Further cardiovascular OUtcomes Research

More information

The CARI Guidelines Caring for Australians with Renal Impairment. Cardiovascular Risk Factors

The CARI Guidelines Caring for Australians with Renal Impairment. Cardiovascular Risk Factors Cardiovascular Risk Factors ROB WALKER (Dunedin, New Zealand) Lipid-lowering therapy in patients with chronic kidney disease Date written: January 2005 Final submission: August 2005 Author: Rob Walker

More information

PCSK9 Agents Drug Class Prior Authorization Protocol

PCSK9 Agents Drug Class Prior Authorization Protocol PCSK9 Agents Drug Class Prior Authorization Protocol Line of Business: Medicaid P & T Approval Date: February 21, 2018 Effective Date: April 1, 2018 This policy has been developed through review of medical

More information

Elements for a Public Summary

Elements for a Public Summary Rosuvastatin Stada 5 mg film-coated tablets Rosuvastatin Stada 10 mg film-coated tablets Rosuvastatin Stada 20 mg film-coated tablets Rosuvastatin Stada 40 mg film-coated tablets 25.8.2014, V1.1 PUBLIC

More information

The Clinical Unmet need in the patient with Diabetes and ACS

The Clinical Unmet need in the patient with Diabetes and ACS The Clinical Unmet need in the patient with Diabetes and ACS Professor Kausik Ray (UK) BSc(hons), MBChB, MD, MPhil, FRCP (lon), FRCP (ed), FACC, FESC, FAHA Diabetes is a global public health challenge

More information

Package leaflet: Information for the user. Ezetimibe STADA 10 mg, tabletten. Ezetimibe

Package leaflet: Information for the user. Ezetimibe STADA 10 mg, tabletten. Ezetimibe Package leaflet: Information for the user Ezetimibe STADA 10 mg, tabletten Ezetimibe Read all of this leaflet carefully before you start taking this medicine because it contains important information for

More information

New Guidelines in Dyslipidemia Management

New Guidelines in Dyslipidemia Management The Fourth IAS-OSLA Course on Lipid Metabolism and Cardiovascular Risk Muscat, Oman, February 2018 New Guidelines in Dyslipidemia Management Dr. Khalid Al-Waili, MD, FRCPC, DABCL Senior Consultant Medical

More information

Making War on Cholesterol with New Weapons: How Low Can We/Should We Go? Shaun Goodman

Making War on Cholesterol with New Weapons: How Low Can We/Should We Go? Shaun Goodman Making War on Cholesterol with New Weapons: How Low Can We/Should We Go? Shaun Goodman Disclosures Research grant support, speaker/consulting honoraria: Sanofi and Regeneron Including ODYSSEY Outcomes

More information

TRANSPARENCY COMMITTEE OPINION. 4 November 2009

TRANSPARENCY COMMITTEE OPINION. 4 November 2009 The legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION 4 November 2009 RANEXA 375 mg extended release tablet Pack of 60 (CIP: 394 370-7) RANEXA 500 mg extended release tablet

More information

ATP IV: Predicting Guideline Updates

ATP IV: Predicting Guideline Updates Disclosures ATP IV: Predicting Guideline Updates Daniel M. Riche, Pharm.D., BCPS, CDE Speaker s Bureau Merck Janssen Boehringer-Ingelheim Learning Objectives Describe at least two evidence-based recommendations

More information

Identification and management of familial hypercholesterolaemia (FH) - An overview

Identification and management of familial hypercholesterolaemia (FH) - An overview Identification and management of familial hypercholesterolaemia (FH) - An overview National Collaborating Centre for Primary Care and Royal College of General Practitioners NICE Guideline CG 71 (August

More information

Cost-effectiveness of evolocumab (Repatha ) for hypercholesterolemia

Cost-effectiveness of evolocumab (Repatha ) for hypercholesterolemia Cost-effectiveness of evolocumab (Repatha ) for hypercholesterolemia The NCPE has issued a recommendation regarding the cost-effectiveness of evolocumab (Repatha ). Following NCPE assessment of the applicant

More information

ONE REGIMEN, ALL GENOTYPES, 8 WEEKS

ONE REGIMEN, ALL GENOTYPES, 8 WEEKS For UK healthcare professionals only INTRODUCING MAVIRET ONE REGIMEN, ALL GENOTYPES, 8 WEEKS FOR TREATMENT-NAÏVE, NON-CIRRHOTIC PATIENTS 1 Maviret is indicated for the treatment of chronic hepatitis C

More information

Disclosures No relationships (not even to an employer) No off-label uses. Cholesterol Lowering Guidelines: What now?

Disclosures No relationships (not even to an employer) No off-label uses. Cholesterol Lowering Guidelines: What now? Disclosures No relationships (not even to an employer) No off-label uses Cholesterol Lowering Guidelines: What now?, FACP 1 2 65-year-old white woman Total cholesterol 175mg/dL HDL 54 mg/dl LDL 96 mg/dl

More information

Elements for a Public Summary

Elements for a Public Summary VI.2 Elements for a Public Summary [Product name] 10 mg film-coated tablets, [Product name] 20 mg film-coated tablets [Product name] 30 mg film-coated tablets [Product name] 40 mg film-coated tablets [Product

More information

SUMMARY OF PRODUCT CHARACTERISTICS. Each film-coated tablet contains 10 mg of atorvastatin (as atorvastatin Calcium trihydrate).

SUMMARY OF PRODUCT CHARACTERISTICS. Each film-coated tablet contains 10 mg of atorvastatin (as atorvastatin Calcium trihydrate). SUMMARY OF PRODUCT CHARACTERISTICS 1. NAME OF THE MEDICINAL PRODUCT Atorvastatine STADA 10 mg, filmomhulde tabletten Atorvastatine STADA 20 mg, filmomhulde tabletten Atorvastatine STADA 40 mg, filmomhulde

More information

Drug Class Monograph

Drug Class Monograph Drug Class Monograph Class: Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Inhibitor Drugs: Praluent (alirocumab), Repatha (evolocumab) Line of Business: Medi-Cal Effective Date: February 17, 2016

More information

Preventive Cardiology Scientific evidence

Preventive Cardiology Scientific evidence Preventive Cardiology Scientific evidence Professor David A Wood Garfield Weston Professor of Cardiovascular Medicine International Centre for Circulatory Health Imperial College London Primary prevention

More information

LIST OF ABBREVIATIONS

LIST OF ABBREVIATIONS Diabetes & Endocrinology 2005 Royal College of Physicians of Edinburgh Diabetes and lipids 1 G Marshall, 2 M Fisher 1 Research Fellow, Department of Cardiology, Glasgow Royal Infirmary, Glasgow, Scotland,

More information

New Guidelines in Dyslipidemia Management

New Guidelines in Dyslipidemia Management The Third IAS-OSLA Course on Lipid Metabolism and Cardiovascular Risk Muscat, Oman, February 2017 New Guidelines in Dyslipidemia Management Dr. Khalid Al-Waili, MD, FRCPC, DABCL Senior Consultant Medical

More information

Elements for a Public Summary. Overview of disease epidemiology. Cardiovascular Events

Elements for a Public Summary. Overview of disease epidemiology. Cardiovascular Events VI.2 VI.2.1 Elements for a Public Summary Overview of disease epidemiology Cardiovascular Events Each year cardiovascular disease (CVD) causes 3.9 million deaths in Europe and over 1.8 million deaths in

More information

Dyslipidemia: Lots of Good Evidence, Less Good Interpretation.

Dyslipidemia: Lots of Good Evidence, Less Good Interpretation. Dyslipidemia: Lots of Good Evidence, Less Good Interpretation. G Michael Allan Evidence & CPD Program, ACFP Associate Professor, Dept of Family, U of A. CFPC CoI Templates: Slide 1 Faculty/Presenter Disclosure

More information

srmp Atorvastatin Medical Valley

srmp Atorvastatin Medical Valley srmp Atorvastatin Medical Valley VI.2 VI.2.1 Elements for a public summary Overview of disease epidemiology This product is indicated for the lowering of cholesterol blood levels and the prevention of

More information

MOLINA HEALTHCARE OF CALIFORNIA

MOLINA HEALTHCARE OF CALIFORNIA MOLINA HEALTHCARE OF CALIFORNIA HIGH BLOOD CHOLESTEROL IN ADULTS GUIDELINE Molina Healthcare of California has adopted the Third Report of the National Cholesterol Education Program (NCEP) Expert Panel

More information

NATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE

NATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE NATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE QUALITY AND OUTCOMES FRAMEWORK (QOF) INDICATOR DEVELOPMENT PROGRAMME Briefing paper QOF indicator area: Peripheral arterial disease Potential output:

More information

The TNT Trial Is It Time to Shift Our Goals in Clinical

The TNT Trial Is It Time to Shift Our Goals in Clinical The TNT Trial Is It Time to Shift Our Goals in Clinical Angioplasty Summit Luncheon Symposium Korea Assoc Prof David Colquhoun 29 April 2005 University of Queensland, Wesley Hospital, Brisbane, Australia

More information

2016 ESC/EAS Guideline in Dyslipidemias: Impact on Treatment& Clinical Practice

2016 ESC/EAS Guideline in Dyslipidemias: Impact on Treatment& Clinical Practice 2016 ESC/EAS Guideline in Dyslipidemias: Impact on Treatment& Clinical Practice Nattawut Wongpraparut, MD, FACP, FACC, FSCAI Associate Professor of Medicine, Division of Cardiology, Department of Medicine

More information

Clinical Policy: Pitavastatin (Livalo), Ezetimibe/Simvastatin (Vytorin 10/10 mg) Reference Number: CP.CPA.62 Effective Date:

Clinical Policy: Pitavastatin (Livalo), Ezetimibe/Simvastatin (Vytorin 10/10 mg) Reference Number: CP.CPA.62 Effective Date: Clinical Policy: Pitavastatin (Livalo), Ezetimibe/Simvastatin (Vytorin 10/10 mg) Reference Number: CP.CPA.62 Effective Date: 11.16.16 Last Review Date: 11.17 Line of Business: Commercial Revision Log See

More information

Hyperlipidaemia, dyslipidaemia and hypercholesterolaemia

Hyperlipidaemia, dyslipidaemia and hypercholesterolaemia Medicine > Cardiology > Hyperlipidaemia, dyslipidaemia and Background information Patient information including patient decision aid Key messages for this pathway FH specialist nurse contact details Local

More information

Lipids: new drugs, new trials, new guidelines

Lipids: new drugs, new trials, new guidelines Lipids: new drugs, new trials, new guidelines Milan Gupta, MD, FRCPC, FCCS State of the Heart Co-Chair Associate Clinical Professor of Medicine, McMaster University Assistant Professor of Medicine, University

More information

Ezetimib Stada 10 mg tablets

Ezetimib Stada 10 mg tablets Ezetimib Stada 10 mg tablets 13.7.2016, Version V1.3 PUBLIC SUMMARY OF THE RISK MANAGEMENT PLAN VI.2 Elements for a Public Summary Ezetimib Stada 10 mg tablets VI.2.1 Overview of disease epidemiology Having

More information

Package leaflet: Information for the patient. Ezetimibe 10 mg tablets ezetimibe

Package leaflet: Information for the patient. Ezetimibe 10 mg tablets ezetimibe Package leaflet: Information for the patient Ezetimibe 10 mg tablets ezetimibe Read all of this leaflet carefully before you start taking this medicine because it contains important information for you.

More information

TRANSPARENCY COMMITTEE OPINION. 27 May 2009

TRANSPARENCY COMMITTEE OPINION. 27 May 2009 The legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION 27 May 2009 INEGY 10 mg/20 mg, tablet B/30 (CIP code: 369 613-7) INEGY 10 mg/40 mg, tablet B/30 (CIP code: 369 616-6)

More information

However, if instead, CHD risk is plotted on a doubling scale (as in slide 2) then there is a

However, if instead, CHD risk is plotted on a doubling scale (as in slide 2) then there is a Slides 1 and 2: These two illustrative slides (based on notionaldata) were used in my presentation to Dr Godlee at our meeting on 2 December 2013 to show that, if the risk of coronary disease (CHD) is

More information

NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE General practice Indicators for the NICE menu

NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE General practice Indicators for the NICE menu NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE General practice Indicators for the NICE menu Indicator area: Pulse rhythm assessment for AF Indicator: NM146 Date: June 2017 Introduction There is evidence

More information

Effective Treatment Options With Add-on or Combination Therapy. Christie Ballantyne (USA)

Effective Treatment Options With Add-on or Combination Therapy. Christie Ballantyne (USA) Effective Treatment Options With Add-on or Combination Therapy Christie Ballantyne (USA) Effective treatment options with add-on or combination therapy Christie M. Ballantyne, MD Center for Cardiovascular

More information

Elements for a Public Summary

Elements for a Public Summary VI.2 Elements for a Public Summary / / 10 mg/10 mg tablets / / 10 mg/20 mg tablets / / 10 mg/40 mg tablets / / 10 mg/80 mg tablets VI.2.1 Overview of disease epidemiology Prevention of cardiovascular events

More information

Dyslipedemia New Guidelines

Dyslipedemia New Guidelines Dyslipedemia New Guidelines New ACC/AHA Prevention Guidelines on Blood Cholesterol November 12, 2013 Mohammed M Abd El Ghany Professor of Cardiology Cairo Universlty 1 1 0 Cholesterol Management Pharmacotherapy

More information

Type 2 Diabetes. Stopping Smoking. Consider referral to smoking cessation. Consider referring for weight management advice.

Type 2 Diabetes. Stopping Smoking. Consider referral to smoking cessation. Consider referring for weight management advice. Type 2 Diabetes Stopping Smoking Consider referral to smoking cessation BMI > 25 kg m² Set a weight loss target of a 5-10% reduction Consider referring for weight management advice Control BP to

More information

Common Repatha Documentation Requirements for Patients With Primary Hyperlipidemia and Established CVD 1,2

Common Repatha Documentation Requirements for Patients With Primary Hyperlipidemia and Established CVD 1,2 Established CVD Common Repatha Documentation Requirements for Patients With Primary Hyperlipidemia and Established CVD 1,2 Primary and Secondary Diagnosis Codes Primary Diagnosis: Primary hyperlipidemia

More information

Helen Williams Consultant Pharmacist for CV Disease - South London

Helen Williams Consultant Pharmacist for CV Disease - South London Helen Williams Consultant Pharmacist for CV Disease - South London CVD remains the leading cause of death in the UK Accounts for a third of all deaths 46,000 deaths in people < 75 years (70% of these

More information

PRESCRIBING INFORMATION (PI)

PRESCRIBING INFORMATION (PI) PRESCRIBING INFORMATION (PI) BYDUREON (exenatide) 2MG POWDER AND SOLVENT FOR PROLONGED-RELEASE SUSPENSION FOR INJECTION BYETTA (exenatide) 5 MICROGRAMS AND 10 MICROGRAMS SOLUTION FOR INJECTION, PREFILLED

More information

Cardiovascular Management of a Patient with Diabetes

Cardiovascular Management of a Patient with Diabetes Cardiovascular Management of a Patient with Diabetes Dr Jeremy Krebs Clinical Leader Endocrinology and Diabetes Wellington Hospital Summary People with diabetes take a lot of medication Compliance and

More information

SUMMARY OF PRODUCT CHARACTERISTICS

SUMMARY OF PRODUCT CHARACTERISTICS SUMMARY OF PRODUCT CHARACTERISTICS 1. NAME OF THE MEDICINAL PRODUCT Pravastatin sodium 10 mg Tablets 2. QUALITATIVE AND QUANTITATIVE COMPOSITION Each tablet contains pravastatin sodium 10 mg. Each tablet

More information